Valuation: IN8bio, Inc.

Market Cap 9.36M 8.34M 7.65M 6.95M 13.08M 886M 13.37M 91.02M 36.58M 468M 35.14M 34.39M 1.48B P/E 2026 *
-0.85x
P/E 2027 * -1x
Enterprise Value 9.36M 8.34M 7.65M 6.95M 13.08M 886M 13.37M 91.02M 36.58M 468M 35.14M 34.39M 1.48B EV / Sales 2026 *
-
EV / Sales 2027 * 8.46x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day-2.02%
1 week-3.05%
Current month+3.26%
1 month-33.52%
3 months-3.05%
6 months-37.95%
Current year-60.23%
1 week 0.9
Extreme 0.9001
1.01
1 month 0.87
Extreme 0.87
1.45
Current year 0.87
Extreme 0.87
2.73
1 year 0.87
Extreme 0.87
2.73
3 years 0.87
Extreme 0.87
74.4
5 years 0.87
Extreme 0.87
282.72
10 years 0.87
Extreme 0.87
309.57
Manager TitleAgeSince
Chief Executive Officer 50 31/10/2015
Chief Tech/Sci/R&D Officer 72 31/10/2018
Director of Finance/CFO 43 07/02/2021
Director TitleAgeSince
Director/Board Member 50 31/10/2015
Director/Board Member 68 30/06/2019
Director/Board Member 64 03/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Don

Director

-724,637 7.3589%
09/05/26 Free

Chairman

22,000 0.2234%
09/05/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
-2.02%-3.05%-50.49%-97.02% 9.36M
+10.00%+5.18%+54.35%+71.20% 60.57B
+1.44%+4.06%+22.70%+101.03% 55.51B
+3.32%+4.11%+14.82%+75.04% 55.22B
+0.46%-2.86%+23.34%+33.77% 43.27B
+6.42%+3.20%+21.14%+105.56% 40.36B
+2.82%+7.24%+236.59%+801.17% 41.63B
-3.79%+19.39%+91.90%+77.13% 33.29B
+5.32%+6.04%+20.27%+52.98% 32.27B
+5.32%+15.84%-40.93%+342.66% 22.91B
Average +2.93%+4.41%+39.37%+156.35% 38.5B
Weighted average by Cap. +3.72%+4.06%+51.57%+169.51%

Financials

2026 *2027 *
Net sales - 1.11M 985K 904K 821K 1.55M 105M 1.58M 10.75M 4.32M 55.35M 4.15M 4.06M 175M
Net income -20.96M -18.66M -17.12M -15.56M -29.29M -1.98B -29.93M -204M -81.89M -1.05B -78.68M -77M -3.32B -23.72M -21.12M -19.38M -17.61M -33.15M -2.25B -33.87M -231M -92.67M -1.19B -89.04M -87.14M -3.76B
Net Debt - -
Projected Income Statement - Annual - IN8bio, Inc.
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
04/11/26 US$0.9377 -1.28% 107,526
03/11/26 US$0.9499 +4.38% 20,360
02/11/26 US$0.9100 +0.97% 9,332
30/10/26 US$0.9013 -8.04% 47,935
29/10/26 US$0.9801 -3.91% 1,419
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - IN8bio, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9377USD
Average target price
7.000USD
Spread / Average Target
+646.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - IN8bio, Inc.
  1. Stock Market
  2. Stocks
  3. INAB Stock